Applying Shear Wave Elastography for Adjunct Steroid on Tuberculous Lymphadenitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. To prospectively collect the radiologic data from the initial phase till the post-treatment phase of tuberculous lymphadenitis.
2. To prospectively investigate the benefits of corticosteroid on reduction of paradoxical upgrading reaction in patients with tuberculous lymphadenitis based on the results of shear wave elastography.
3. To investigate the potential biomarker of host immunity in response to tuberculosis and predict the development of paradoxical upgrading reaction.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study on Endobronchial Ultrasound-guided Transbronchial Mediastinal Cryobiopsy Via a Tunnel in the Diagnosis of Mediastinal Lymphadenopathy

NCT05803239

Mediastinal Lymphadenopathy

COMPLETED NA

Diagnosis of Mediastinal Tuberculous Lymphadenopathy by Endobronchial Ultrasound-guided Transbronchial Needle Aspiration (EBUS-TBNA)

NCT01121432

Mediastinal Lymphadenopathy Tuberculous Mediastinal Lymphadenopathy

UNKNOWN

Ultrasound Elastography of Breast Lesions

NCT00716482

Breast Neoplasms

COMPLETED

Application of Transthoracic Shear-wave Ultrasound Elastography in Pleural Lesions

NCT04781894

Elasticity Imaging Techniques

RECRUITING

Ultrasonographic Differentiation Between Kikuchi's Disease and Lymphoma in Patients With Cervical Lymphadenopathy

NCT01310933

Lymphoma Kikuchi's Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tuberculosis remained one of the top ten leading cause of death worldwide. There were more than 10 million new diagnoses per year, and up to 1.2 million deaths caused by tuberculosis. Extra-pulmonary tuberculosis is defined as infection outside the lung. Tuberculous lymphadenitis is the most common site of extra-pulmonary tuberculosis, constituting around 30-50% of all cases. A unique manifestation with worsening of symptoms, called paradoxical upgrading reaction (PUR), may develop in 20-50% of patients with tuberculous lymphadenitis during the therapy. Common presentations of the PUR include swollen lymphadenitis with pain or rupture with pus. Patients may fail to complete the treatment and jeopardize the development of drug-resistant pathogen. Limited studies investigated the risk factors associated with the PUR. In our prior study, ultrasound shear wave elastography offers quantified values as the objective parameters to successfully predict the occurrence of PUR. In this study, we aim to investigate the effect of corticosteroid as an adjunct therapy to reduce the PUR from happening in patients with tuberculous lymphadenitis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculous Lymphadenitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adjunct corticosteroid and standard anti-tuberculosis agent

Prednisolone dosing and duration per study protocol

Group Type EXPERIMENTAL

Prednisolone

Intervention Type DRUG

adjunct steroid per study protocol

standard anti-tuberculosis agents

Intervention Type DRUG

standard anti-tuberculosis agents

Standard of care with standard anti-tuberculosis agent

standard anti-tuberculosis agent

Group Type ACTIVE_COMPARATOR

standard anti-tuberculosis agents

Intervention Type DRUG

standard anti-tuberculosis agents

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prednisolone

adjunct steroid per study protocol

Intervention Type DRUG

standard anti-tuberculosis agents

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants diagnosed of tuberculous lymphadenitis.
* The diagnosis of tuberculous lymphadenitis must qualify any of the following criteria:

1. microbiological evidence (culture or nucleic acid amplification test)
2. histology specimen featuring caseating granulomatous inflammation with acid-fast bacilli on smear, or clinical response to anti-tuberculosis therapy.

Exclusion Criteria

* Participants with age \< 18 years
* Diagnoses based on histologic report turned out to be non-tuberculosis mycobacterial infection
* The tuberculous lymphadenitis involved was surgically removed, without available target to be monitored
* Participant under systemic (oral or parenteral) steroid therapy.
* Participant with active hepatitis B virus infection
* Participant reluctant to be enrolled in the trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No